Clinical trial · Interventional
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 1 Study of CCI-779 in Combination With Dexamethasone in Multiple Myeloma
NCT00693433CI-TRIAL-00020068completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This phase I trial is studying the side effects and best dose of temsirolimus when given together with dexamethasone in treating patients with recurrent or refractory multiple myeloma. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving temsirolimus together with dexamethasone may kill more cancer cells.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Refractory Multiple Myeloma | Multiple Myeloma | CURATED_BROADER | 0.78 |
| Stage III Multiple Myeloma | Multiple Myeloma | CURATED_BROADER | 0.78 |
| Stage II Multiple Myeloma | Multiple Myeloma | CURATED_BROADER | 0.78 |
| Stage I Multiple Myeloma | Multiple Myeloma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dexamethasone | Drug | Dexamethasone | ALIAS |
| laboratory biomarker analysis | Other | — | UNRESOLVED |
| temsirolimus | Drug | Temsirolimus | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (enzyme inhibitor, chemotherapy)
- description
- Patients receive temsirolimus IV over 30 minutes once weekly on days 1, 8, 15, and 22 and oral dexamethasone once on days 1, 2, 8, 9, 15, 16, 22, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- interventionNames
- Drug: dexamethasone
- Drug: temsirolimus
- Other: laboratory biomarker analysis
Primary outcomes (2)
- measure
- Maximum tolerated dose of temsirolimus
- timeFrame
- Course 1 (first 28 days)
- description
- The MTD is the dose level at which less than 2 out of 6 subjects experience DLT. Assessed according to the NCI Common Toxicity Criteria (CTC).
- measure
- Toxicity and safety
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
* Pathologically confirmed multiple myeloma
* Measurable levels of M protein in serum and/or urine
* Recurrent or refractory disease
* Progressive disease after treatment with ≥ 2 separate chemotherapeutic regimens
* At least 1 of the regimens must have included high-dose dexamethasone (40 mg on days 1-4, 9-12, and 17-20) or medium-dose dexamethasone (40 mg on days 1, 8, 15, and 22) of a 28-day course
* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
* Life expectancy ≥ 8 weeks
* Absolute neutrophil count \> 1,000/mm\^3
* Platelet count \> 100,000/mm \^3
* Total bilirubin \< 2 mg/dL
* AST and ALT \< 3 times upper limit of normal
* Creatinine \< 2 mg/dL
* Fasting cholesterol \< 350 mg/dL
* Fasting triglycerides \< 400 mg/dL
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No history of allergic reactions attributed to compounds of similar chemical or biological composition to temsirolimus or dexamethasone
* No concurrent uncontrolled illness including, but not limited to, any of the following:
* Ongoing or active infection
* Poorly controlled hypertension
* Diabetes mellitus
* Symptomatic congestive heart failure
* Unstable angina pectoris
* Cardiac arrhythmia
* Psychiatric illness or social situation that would limit compliance with study requirements
* See Disease Characteristics
* At least 4 weeks since prior cytotoxic therapy
* More than 4 weeks since prior chemotherapy and recovered
* No concurrent anticonvulsive or antiarrhythmic medications
* No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital) or other CYP3A4 inhibitors or inducers (e.g., rifampin or Hypericum perforatum \[St. John wort\])
* No concurrent prophylactic hematopoietic colony-stimulating factors
* No other concurrent investigational therapy
* No other concurrent anticancer therapyReferences
Publications (0)
Data not yet available
No reference posted for this study.